Autopsy report · NCT01650909

The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU

“Withdrawn due to no funding”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Stanford University

Sponsor type

University, hospital or other

Conditions

Classical Phenylketonuria(PKU)

Participants

0

Trials that died the same way

• Hydroxychloroquine Efficacy in Chronic Urticaria
  “withdrawn, not funded” (92% match in meaning)
• Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
  “funding withdrawn” (89% match in meaning)
• Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer
  “funding was withdrawn” (88% match in meaning)
• Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder
  “Funding withdrawn due to inability to accrue” (88% match in meaning)
• MAGIK for Femoral/Tibial Shaft Fractures
  “Withdrawn due to lack of funding.” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.